Patents by Inventor Fei Xiong

Fei Xiong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090041768
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 12, 2009
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Publication number: 20090022744
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Application
    Filed: August 1, 2008
    Publication date: January 22, 2009
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Publication number: 20090012272
    Abstract: The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain.
    Type: Application
    Filed: August 1, 2008
    Publication date: January 8, 2009
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Patent number: 7442778
    Abstract: The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacologic agent comprising an amino acid sequence of the selected peptide in a loop region of an Fc domain. This process may be employed to modify an Fc domain that is already linked through an N- or C-terminus or sidechain to a peptide or to a polypeptide (e.g., etanercept). This process may also be employed to modify an Fc domain that is part of an antibody (e.g., adalimumab, epratuzumab, infliximab, Herceptin®, and the like). In this way, different molecules can be produced that have additional functionalities, such as a binding domain to a different epitope or an additional binding domain to the precursor molecule's existing epitope.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: October 28, 2008
    Assignee: Amgen Inc.
    Inventors: Colin Gegg, Fei Xiong, Karen C. Sitney
  • Publication number: 20070269369
    Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.
    Type: Application
    Filed: August 10, 2006
    Publication date: November 22, 2007
    Inventors: Colin Gegg, Kenneth Walker, Leslie Miranda, Fei Xiong
  • Patent number: 7259137
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 21, 2007
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Patent number: 7221670
    Abstract: An A.S0001/IS-2001 based Access Network for packet data has a base station (BS), a packet control function (PCF), and a packet data serving node (PDSN). If a BS/PCF connection fails to be achieved, this is communicated from the PDSN to the PCF by a message that identifies a reason for the failure to register selected from a plurality of possible reasons. A similar message is sent from the PCF to the BS informing the BS of the reason for the failure to register. If the PDSN/PCF interface is released after being connected, this is communicated from the PDSN to the PCF by a message that identifies the reason for the release selected from a plurality of possible reasons. A similar message is sent from the PCF to the BS so that the BS is informed of the reason for the release.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: May 22, 2007
    Assignee: Motorola, Inc.
    Inventors: Shahab M. Sayeedi, Fei Xiong, Kim Sun Loh
  • Publication number: 20060291384
    Abstract: A call where a packet discard policy (132) should be applied is selectively identified based upon a received property associated with the call. The packet discard policy (132) is applied to the selected call in order to selectively discard packets (134) associated with the call when a triggering event (136) occurs.
    Type: Application
    Filed: June 28, 2005
    Publication date: December 28, 2006
    Inventors: John Harris, Ronald Crocker, Joseph Sullivan, Yehezkel Halifa, Lizi Patlajan, Fei Xiong
  • Publication number: 20060140934
    Abstract: The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacologic agent comprising an amino acid sequence of the selected peptide in a loop region of an Fc domain. This process may be employed to modify an Fc domain that is already linked through an N— or C-terminus or sidechain to a peptide or to a polypeptide (e.g., etanercept). This process may also be employed to modify an Fc domain that is part of an antibody (e.g., adalimumab, epratuzumab, infliximab, Herceptin®, and the like). In this way, different molecules can be produced that have additional functionalities, such as a binding domain to a different epitope or an additional binding domain to the precursor molecule's existing epitope.
    Type: Application
    Filed: September 23, 2005
    Publication date: June 29, 2006
    Inventors: Colin Gegg, Fei Xiong, Karen Sitney
  • Publication number: 20060135431
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Application
    Filed: November 10, 2005
    Publication date: June 22, 2006
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Publication number: 20060116151
    Abstract: A communication system provides for an expedited response to an invitation to a Push-to-Talk (PTT) communication session from a terminating side of the communication system when a target mobile station (MS) is not currently available to participate in a PTT communication session by responding to a PTT session invitation prior to an expiration of a second, Paging timer and after a predetermined number of expirations of a first, Tbsreq9 timer or after a predetermined number of unsuccessful requests to page the target MS. In another embodiment of the invention, the communication system may further consider the contents of a downlink buffer of a terminating side Packet Control Function in determining whether and when to respond to an invitation to a PTT communication session, utilizing a third, TpagingBackoff timer in determining when to request a page of a non-responsive target MS.
    Type: Application
    Filed: January 9, 2006
    Publication date: June 1, 2006
    Inventors: Joseph Sullivan, Ronald Crocker, Yehezkel Halifa, Lizi Patlajan, Fei Xiong, John Harris, Thomas Hallin
  • Publication number: 20030195156
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae 1 (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ.
    Type: Application
    Filed: May 13, 2002
    Publication date: October 16, 2003
    Applicant: Amgen Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Publication number: 20030195154
    Abstract: The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.
    Type: Application
    Filed: April 3, 2003
    Publication date: October 16, 2003
    Inventors: Kenneth Walker, Fei Xiong
  • Publication number: 20030191056
    Abstract: The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.
    Type: Application
    Filed: April 4, 2002
    Publication date: October 9, 2003
    Inventors: Kenneth Walker, Fei Xiong
  • Publication number: 20030031159
    Abstract: An A.S0001/IS-2001 based Access Network for packet data has a base station (BS), a packet control function (PCF), and a packet data serving node (PDSN). If a BS/PCF connection fails to be achieved, this is communicated from the PDSN to the PCF by a message that identifies a reason for the failure to register selected from a plurality of possible reasons. A similar message is sent from the PCF to the BS informing the BS of the reason for the failure to register. If the PDSN/PCF interface is released after being connected, this is communicated from the PDSN to the PCF by a message that identifies the reason for the release selected from a plurality of possible reasons. A similar message is sent from the PCF to the BS so that the BS is informed of the reason for the release.
    Type: Application
    Filed: August 6, 2002
    Publication date: February 13, 2003
    Inventors: Shahab M. Sayeedi, Fei Xiong, Kim Sun Loh